Medical Radiology and Radiation Safety. 2022. Vol. 67. № 5
DOI: 10.33266/1024-6177-2022-67-5-80-85
V.I. Chernov1, 2, E.A. Dudnikova1, V.E. Goldberg1, A.V. Goldberg1,
T.L. Kravchuk1, A.V. Muravleva1, R.V. Zelchan1, 2, A.A. Medvedeva1,
O.D. Bragina1, 2, A.N. Rybina1
SINGLE-PHOTON EMISSION COMPUTERIZED TOMOGRAPHY
WITH 99mTC-1-THIO-D-GLUCOSE IN THE STAGING
OF LYMPHOMAS
1Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia
2 Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences,
Tomsk Polytechnic University, Tomsk, Russia
Contact person: V.I. Chernov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To study the possibility of using SPECT with a new radiopharmaceutical 99mTc-1-thio-D-glucose (99mTc-TG) for staging lymphomas.
Material and methods: The study included 53 patients with a verified diagnosis of lymphoma (38 people – the main group) and adenopathy of non-tumor origin (15 patients - the comparison group). All patients of the main group underwent 99mTc-TG SPECT, CT of the chest, abdominal organs and all interested areas, ultrasound, and biopsy followed by histological and immunohistochemical studies. Five patients underwent additional 18F-FDG PET/CT. The reference verification methods were histological and IHC examination or, if it was impossible to perform it, clinical observation of the patient for a year with standard control instrumental studies, 18F-FDG PET/CT and 99mTc-TG SPECT. In the comparison group, 99mTc-TG SPECT was performed once before the biopsy.
Results: It was shown that 99mTc-TG SPECT made it possible to identify hypermetabolic foci in 75 % of the affected lymph nodes and in
81 % of extranodal formations established by reference diagnostic methods. The low sensitivity 99mTc-TG SPECT are due to the low diagnostic efficiency of the method in detecting lesions in the abdominal cavity and are associated with a high background blood activity and a physiological increase in the accumulation of 99mTc-TG in the kidneys and bladder. However, the method allowed additional visualization of nodal and extranodal lesions in 7 and 9 % of cases, respectively. However, the method allowed additional visualization of nodal and extranodal lesions in 7 % and 9 % of cases, respectively. A study of persons in the comparison group showed that 99mTc-TG SPECT has a high specificity (93 %) in the diagnosis of lymphomas.
Conclusion: The 99mTc-TG SPECT with has a high specificity (93 %) in the diagnosis of lymphomas and can be used as an additional method of investigation in the staging of lymphoproliferative diseases.
Keywords: lymphomas, Hodgkin’s lymphoma, non-Hodgkin’s lymphomas, single-photon emission computed tomography, 99mTc-1-Thio -D-glucose
For citation: Chernov VI, Dudnikova EA, Goldberg VE, Goldberg AV, Kravchuk TL, Muravleva AV, Zelchan RV, Medvedeva AA, Bragina OD, Rybina AN. Single-photon Emission Computerized Tomography with 99mTc-1-Thio-D-glucose in the Staging of Lymphomas. Medical Radiology and Radiation Safety. 2022;67(5):80–85. (In Russian). DOI: 10.33266/1024-6177-2022-67-5-80-85
References
1.Rossiyskiye Klinicheskiye Rekomendatsii po Diagnostike i Lecheniyu Zlokachestvennykh Limfoproliferativnykh Zabolevaniy = Russian Clinical Guidelines for the Diagnosis and Treatment of Malignant Lymphoproliferative Diseases.
Ed. Poddubnaya I.V., Savchenko V.G. 2018. 470 p. URL: https://rusoncohem.ru/klinrec/klin-rekomendatsii-limfoproliferativnykh-zabolevaniy/(In Russ.).
2.Barrington S.F., Mikhaeel N.G., Kostakoglu L., Meignan M., Hutchings M., Müeller S.P., et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J. Clin. Oncol. 2014;32:3048–3058. DOI: 10.1200/JCO.2013.53.5229.
3.Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E., et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: the Lugano classification. J. Clin. Oncol. 2014;32:3059–3068. DOI: 10.1200/JCO.2013.54.8800.
4.Dreyling M., Thieblemont C., Gallamini A., Arcaini L., Campo E., Hermine O., et al. ESMO Consensus Conferences: Guidelines On Malignant Lymphoma. Part 2. Marginal Zone Lymphoma, Mantle Cell Lymphoma, Peripheral T-Cell Lymphoma. Ann. Oncol. 2013;24:857–877. DOI:- 10.1093/annonc/mds643.
5.Chernov V.I., Dudnikova Ye.A., Goldberg V.Ye., et al. Positron Emission Tomography in the Diagnosis and Monitoring of Lymphomas. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2018;63;6:41–50. DOI: 10.12737/article_5c0b8d72a8bb98.40545646
(In Russ.).
6.Chanchikova N.G., Dudnikova Ye.A., Karlova Ye.A., et al. Possibilities of 18F-FDG PET/CT in the Diagnosis and Staging of Lymphomas. Voprosy Onkologii = Problems in Oncology. 2019;65;1:147–153. DOI: org/10.37469/0507-3758-2019-65-1-147-153 (In Russ.).
7.Chanchikova N.G., Chernov V.I., Dudnikova Ye.A., et al. The Role of 18F-FDG PET/CT in Evaluation of Therapy Effectiveness and Prognosis of Lymphomas. Byulleten Sibirskoy Meditsiny = Bulletin of Siberian Medicine. 2021;20;2:120–129. DOI: org/10.20538/1682-0363-2021-2-120-129 (In Russ.).
8.Chernov V.I., Dudnikova Ye.A., Goldberg V.Ye., et al. Single-Photon Emission Computerized Tomography in the Diagnosis and Monitoring of Lymphomas. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2019;64;3:58–63. DOI: 10.12737/article_5cf3dfefe60b13.90120976 (In Russ.).
9.Zeltchan R., Medvedeva A., Sinilkin I., et al. Experimental Study of Radiopharmaceuticals Based on Technetium-99m Labeled Derivative of Glucose for Tumor Diagnosis // IOP Conference Series: Materials Science and Engineering. 2016. P. 012054. DOI. 10.1088/1757-899X/135/1/012054.
10.Zelchan R.V., Medvedeva A.A., Sinilkin I.G., et al. The Study of the Functional Suitability of the Tumoritropic Radiopharmaceutical 99mTc-1-Thio-D-Glucose in the Experiment. Molekulyarnaya meditsina = Molecular medicine. 2018.16;2:54–57. DOI: https://doi.org/10.29296/24999490-2018-03-11
(In Russ.).
11.Chernov V.I., Medvedeva A.A., Sinilkin I.G., et al. Development Radiopharmaceuticals for Nuclear Medicine in Oncology. Meditsinskaya vizualizatsiya = Medical Visualization. 2016; 2:63-66 (In Russ.).
12.Chernov V.I., Dudnikova Ye.A., Zelchan R.V., et al. The First Experience of Using 99mTc-1-Thio-D-Glucose for Single-Photon Emission Computed Tomography Imaging of Lymphomas. Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2018;17;4:81–87. DOI: org/10.21294/1814-4861-2018-17-4-81-87 (In Russ.).
13.Dudnikova Ye.A., Chernov V.I., Muravleva A.V., et al. Metabolic Single-Photon Emission Computed Tomography with the New Radiopharmaceutical 99mTc-1-Thio-D-Glucose In the Diagnosis and Monitoring of the Primary Breast Lymphoma (Case Report). Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2020;19;5:145–153. DOI: 10.21294/1814-4861-2020-19-5-145-153 (In Russ.).
14.Muravleva A.V., Chernov V.I., Dudnikova Ye.A., et al. Metabolic Single-Photon Emission Computed Tomography with «99mTc-1-Thio-D-Glucose» – New Possibilities for Hodgkin’s Limphoma Staging. Rossiyskiy Elektronnyy Zhurnal Luchevoy Diagnostiki = Russian Electronic Journal of Radiology. 2021;11;3:171–177. DOI: 10.21569/2222-7415-2021-11-3-171-177 (In Russ.).
15. Chernov V., Dudnikova E., Zelchan R., et al. Phase I Trial of 99mTc-1-Thio-D-Glucose for Imaging of Lymphomas // Preprints. 2022. doi: 10.20944/preprints202205.0028.v1.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.06.2022. Accepted for publication: 25.08.2022.